drugset / Trial / NCT05483023

18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy

NCT05483023

NaSingle-groupOpen-labelDiagnostic

Summary

Purpose: The purpose of this study is to evaluate FFNP PET/MRI's utility for predicting response to Levonorgestrel-releasing Intrauterine Device (LR-IUD) hormonal therapy for Complex Atypical hyperplasia (CAH) and Endometrial Cancer (EC). Participants: Eight women with histologically confirmed CAH or Grade 1 EC who have planned treatment with LR-IUD will be recruited.. Procedures (methods): The is a prospective, single arm, pilot study of 8 participants who will receive one FFNP PET/MRI scan. Medical records will be followed for 6 months.

Timeline

Start
2024-02-15
Primary completion
2026-06-28
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-fluorofuranylnorprogesterone Diagnostic / imaging agent